BOYLE H ET AL: "Treatment of hormone sensitive prostate cancer", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 3, no. 3, October 2005 (2005-10), pages 331-338, XP027683018, ISSN: 1359-6349 [retrieved on 2005-10-01] (B1)

BRACARDA S ET AL: "Cancer of the prostate", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 56, no. 3, December 2005 (2005-12), pages 379-396, XP027789956, ISSN: 1040-8428 [retrieved on 2005-12-01] (B1)

DEBRUYNE FRANS M J: "Gonadotropin-releasing hormone antagonist in the management of prostate cancer", REVIEWS IN UROLOGY, MEDREVIEWS, NEW YORK, US, vol. 6 Suppl 7, January 2004 (2004-01), pages S25-S32, XP002527257, ISSN: 1523-6161 (B1)

DOEHN CHRISTIAN ET AL: "Drug evaluation: Degarelix--a potential new therapy for prostate cancer", IDRUGS, CURRENT DRUGS LTD, GB, vol. 9, no. 8, August 2006 (2006-08), pages 565-572, XP009105353, ISSN: 1369-7056 (B1)

GONZALEZ-BARCENA D ET AL: "Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord", UROLOGY, BELLE MEAD, NJ, US, vol. 45, no. 2, February 1995 (1995-02), pages 275-281, XP002527258, ISSN: 0090-4295, DOI: 10.1016/0090-4295(95)80018-2 (B1)

VAN POPPEL H ET AL: "A ONE-YEAR, MULTICENTRE, RANDOMISED STUDY OF DEGARELIX, A GONADATROPHIN-RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, IN PROSTATE CANCER PATIENTS", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 5, no. 2, April 2006 (2006-04), page 251, XP027163598, ISSN: 1569-9056 [retrieved on 2006-04-01] (B1)

KLOTZ LAURENCE ET AL: "The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.", BJU INTERNATIONAL DEC 2008, vol. 102, no. 11, December 2008 (2008-12), pages 1531-1538, XP002692504, ISSN: 1464-410X (B1)

MONGIAT-ARTUS P ET AL: "Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 4, no. 5, July 2005 (2005-07), pages 4-13, XP027626799, ISSN: 1569-9056 [retrieved on 2005-07-01] (B1)

SORBERA L A ET AL: "Degarelix acetate. GnRH antagonist, prostate cancer therapy", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 31, no. 9, September 2006 (2006-09), pages 755-766, XP002548773, ISSN: 0377-8282, DOI: 10.1358/DOF.2006.031.09.1024366 (B1)

VAN POPPEL H ET AL: "23 LONG-TERM EVALUATION OF DEGARELIX, A GONADOTROPHIN-RELEASING HORMONE (GNRH) RECEPTOR BLOCKER, INVESTIGATED IN A MULTICENTRE RANDOMISED STUDY IN PROSTATE CANCER (CAP) PATIENTS", EUROPEAN UROLOGY SUPPLEMENTS, XX, XX, vol. 6, no. 2, March 2007 (2007-03), page 28, XP027161591, ISSN: 1569-9056 [retrieved on 2007-03-01] (B1)

HUIRNE J A ET AL: "Gonadotropin-releasing-hormone-receptor antagonists", THE LANCET, LANCET LIMITED. LONDON, GB, vol. 358, no. 9295, 24 November 2001 (2001-11-24), pages 1793-1803, XP026794265, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(01)06797-6 [retrieved on 2001-11-24] (B1)